US EUROPE AFRICA ASIA 中文
    China / Society

    Stem-cell trials give new hope to heart patients

    By Shan Juan (China Daily) Updated: 2014-08-26 06:53

    China's patients with chronic heart failure - a serious and common condition in which the heart cannot pump enough blood - will soon have access to the stem-cell-based therapy C-Cure.

    Eight to 10 trial sites are expected to be set up at renowned public medical institutions in Beijing, Shanghai and Guangzhou, in addition to others around the world, to test the safety and effectiveness of the therapy.

    "Participating in the trial will enhance the stem-cell research capacity of China, which remains uncompetitive worldwide," said Zhou Yujie, vice-president of Beijing Anzhen hospital.

    It is the first stem-cell therapy for cardiology to enter Phase 3 of a clinical trial in China, he noted.

    Chronic heart failure affects about 117 million people worldwide, including nearly 30 million in China, according to the World Health Organization and China's National Health and Family Planning Commission.

    Current treatments mainly work to slow down progression of the disease, but with the exception of heart transplants they cannot cure the disease, said professor Gu Hong of Anzhen hospital.

    "C-Cure is a revolutionary stem-cell treatment for heart failure. If it passes the Phase 3 clinical trial, it will enter the market to save the patients," she said.

    The therapy reprograms the patient's own stem cells into new heart cells to rebuild the heart, according to Atta Behfar, director of cardiovascular regeneration at Mayo Clinic in the US.

    He has played an active part in developing the technology that directs the patient's cells to become heart cells. Mayo Clinic was also involved in previous clinical trials of C-Cure in the United States.

    "Stem-cell therapy aims to teach the human body to heal itself and we're moving gradually from promise to reality," he said.

    Xu Guotong, head of the medicine department of Tongji Medical University in Shanghai, agreed but pointed out that China still lags far behind the US.

    "The problem lies in a lack of government regulations and policies," he acknowledged.

    Between a drug and a therapy, stem-cell treatment needs to be clearly defined by the health and drug authorities in China, he said.

    shanjuan@chinadaily.com.cn

    Highlights
    Hot Topics
    ...
    国产成人无码a区在线视频| 亚洲人成中文字幕在线观看 | 国产爆乳无码视频在线观看| 亚洲AV中文无码乱人伦在线观看| 色婷婷久久综合中文久久一本 | 中文字幕VA一区二区三区| 色AV永久无码影院AV| 久久久无码精品亚洲日韩蜜臀浪潮| 国产成人AV一区二区三区无码| 中文字幕无码久久精品青草| 无码性午夜视频在线观看| 精品欧洲av无码一区二区三区| 中文字幕精品无码久久久久久3D日动漫| 综合无码一区二区三区| 亚洲日韩中文在线精品第一 | 成人精品一区二区三区中文字幕 | 中文字幕夜色资源网站| 成人午夜亚洲精品无码网站| 国精品无码一区二区三区在线蜜臀| 日韩精品少妇无码受不了| 日韩精品无码免费专区午夜| 无码137片内射在线影院| 亚洲中文字幕无码爆乳av中文| 日韩精品久久无码人妻中文字幕| 亚洲精品无码专区2| 亚洲中文字幕无码久久2017| 日韩亚洲欧美中文高清在线 | 熟妇人妻系列aⅴ无码专区友真希| 欧美乱人伦人妻中文字幕| 中文字幕 亚洲 有码 在线| 亚洲AV无码专区日韩| 人妻系列无码专区久久五月天| 中文字幕无码久久人妻| 区三区激情福利综合中文字幕在线一区 | 波多野结衣中文字幕在线| 中文字幕有码无码AV| 亚洲天堂2017无码中文| 久久精品天天中文字幕人妻| 中文字幕人妻无码一夲道| 18禁网站免费无遮挡无码中文| 中文字幕一区二区精品区|